Although senior leadership has been re-organized, the actual consistency and interactivity of the team remains stable. In fact, Dr. DiPaola was appointed as Director of CINJ following multiple appointments at CINJ including Co-Leader of the Prostate Program, Chief of Medical Oncology and Associate Director for Clinical Science. Dr. Edmund Lattime, a prior Associate Director, was appointed to the position of Deputy Director in 2008 by Dr. DiPaola. Dr. Joseph R. Bertino remains as Chief Scientific Officer. Dr. Michael Reiss continues as Associate Director for Translational Science and has appropriately assumed oversight of all basic science and translational shared resources. Dr. Eileen White, a Program Leader since 2004, was appointed Associate Director for Basic Science and, following a move of her laboratories to the main CINJ building in New Brunswick, increased basic science mentorship at CINJ. Dr. Joseph Aisner is Associate Director for Clinical Science as in the 2004 review, and Dr. Susan Goodin has been appointed Assistant Director for Clinical Science and Director ofthe Office of Human Research Services. Stability in administration also remains, as Ms. Linda Barker continues as Associate Director for Administration and Planning. As a new leader. Dr. Helmut Zarbl was appointed Associate Director for Public Health Science, overseeing CINJ's efforts in prevention, control, and population science. Salary support for these individuals is requested only for the effort attributable to research-related activities

Public Health Relevance

The senior leadership supports the mission ofthe Cancer Institute of New Jersey (CINJ) as a National Cancer institute (NCI)-designated comprehensive cancer center to increase scientific depth and breadth in basic, clinical and public health sciences.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA072720-14
Application #
8221719
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
14
Fiscal Year
2012
Total Cost
$840,645
Indirect Cost
$122,556
Name
University of Medicine & Dentistry of NJ
Department
Type
DUNS #
617022384
City
Piscataway
State
NJ
Country
United States
Zip Code
08854
Warner, Wayne A; Lee, Tammy Y; Badal, Kimberly et al. (2018) Cancer incidence and mortality rates and trends in Trinidad and Tobago. BMC Cancer 18:712
Qin, Bo; Llanos, Adana A M; Lin, Yong et al. (2018) Validity of self-reported weight, height, and body mass index among African American breast cancer survivors. J Cancer Surviv 12:460-468
Farber, Nicholas J; Radadia, Kushan D; Singer, Eric A (2018) Accuracy of Nodal Staging and Outcomes of Lymphadenectomy for Non-metastatic Renal Cell Carcinoma: An Analysis of the National Cancer Database. Bladder Cancer 4:S14-S15
Poillet-Perez, Laura; Xie, Xiaoqi; Zhan, Le et al. (2018) Autophagy maintains tumour growth through circulating arginine. Nature 563:569-573
Chan, Chang S; Laddha, Saurabh V; Lewis, Peter W et al. (2018) ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun 9:4158
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Warner, Wayne A; Lee, Tammy Y; Fang, Fang et al. (2018) The burden of prostate cancer in Trinidad and Tobago: one of the highest mortality rates in the world. Cancer Causes Control 29:685-697
Zhao, Yuhan; Wu, Lihua; Yue, Xuetian et al. (2018) A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models. Elife 7:
Deek, Matthew P; Kim, Sinae; Ahmed, Inaya et al. (2018) Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer. Am J Clin Oncol 41:362-366
O'Malley, Denalee; Dewan, Asa A; Ohman-Strickland, Pamela A et al. (2018) Determinants of patient activation in a community sample of breast and prostate cancer survivors. Psychooncology 27:132-140

Showing the most recent 10 out of 775 publications